Subsequently, the development of second- and third-generation BCR-ABL inhibitors, such as nilotinib, dasatinib, bosutinib, and ponatinib, expanded options for chronic myeloid leukemia management [102]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.